Cagrilintide

Cagrilintide is a long-acting amylin receptor agonist by Novo Nordisk, most notable as a component of CagriSema — the fixed-dose combination with semaglutide. The combination leverages synergistic mechanisms where semaglutide suppresses appetite and slows gastric emptying while cagrilintide enhances satiety via brainstem pathways and further delays gastric emptying. In the Phase 3 REDEFINE 1 trial, CagriSema achieved 20.4% mean body weight loss at 68 weeks with 60% of participants reaching 20% weight loss and 23% achieving 30%+ weight loss. This represents the highest weight loss efficacy observed in late-stage clinical trials among injectable agents.

10mg